REOLYSIN®
REO 022
Phase 1 mab completed
Quick answer
REOLYSIN® for KRAS Mutant Metastatic Colorectal Cancer is a Phase 1 program (mab) at ONCOLYTICS BIOTECH INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ONCOLYTICS BIOTECH INC
- Indication
- KRAS Mutant Metastatic Colorectal Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- completed